{"id":"W2920183853","doi":"10.1007/s40264-018-00783-1","title":"Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis","year":2019,"lang":"en","type":"review","venue":"Drug Safety","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Victoria Hospital; Western University; University of Calgary; Robarts Clinical Trials","funders":"","keywords":"Vedolizumab; Medicine; Ulcerative colitis; Natalizumab; Adverse effect; Internal medicine; Maintenance therapy; Inflammatory bowel disease; Infliximab; Crohn's disease; Placebo; Gastroenterology; Immunology; Disease; Pathology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002552899,0.0008837289,0.003423807,0.001545979,0.0001692574,0.001214591,0.00130632,0.00148049,0.003160578],"category_scores_gemma":[0.003985273,0.000304996,0.001415741,0.001200199,0.000493506,0.0009524839,0.0005797396,0.002666644,0.0007189353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009586238,"about_ca_system_score_gemma":0.001015631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00115029,"about_ca_topic_score_gemma":0.00222769,"domain_scores_codex":[0.9991965,0.0002743131,0.0001389373,0.00008741907,0.0002629586,0.00003995552],"domain_scores_gemma":[0.997551,0.001806827,0.000314903,0.00002948929,0.0002349149,0.00006286419],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006319146,0.00006267585,0.0002771611,0.02543599,0.001015308,0.0001559222,0.00002644767,0.0007716496,0.0005917673,0.003519984,0.0189933,0.9485178],"study_design_scores_gemma":[0.0009926831,0.0009259816,0.00507818,0.03094844,0.005480769,0.00241653,0.0001008736,0.001126743,0.0008706137,0.01642461,0.9355305,0.0001040646],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009739113,0.9989506,0.0001391362,0.000329839,0.0001163924,0.00000458259,0.00002420985,0.000004089416,0.0003338378],"genre_scores_gemma":[0.002687204,0.995355,0.0004038061,0.000729709,0.0003913211,0.00001540447,0.00005495294,0.000002732319,0.0003598644],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003423807,"threshold_uncertainty_score":0.01350117,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01567007994426291,"score_gpt":0.3114790885300934,"score_spread":0.2958090085858305,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}